23
Participants
Start Date
February 28, 2001
Primary Completion Date
December 31, 2013
Study Completion Date
March 31, 2016
Methotrexate
Methotrexate will be given at a dose of 30mg/m2/week intramuscular (IM) or intravenous (IV) for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first)
Vinblastine
Vinblastine will be given at a dose of 6mg/m2/week intravenous (IV) for for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first). Maximum actual dose may not exceed 10mg.
Children's Hospital of Philadelphia, Philadelphia
Children's Hospital of Philadelphia
OTHER